Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status

Human epidermal growth factor receptor 2 (HER2) signaling pathway activation has been identified as a contributor to de novo or acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in a small subset of patients with metastatic colorectal cancer (mCRC). Dual anti-HER2-targeted tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanat, Ozkan, Ertas, Hulya, Caner, Burcu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2018
Materias:
Minireviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163141/
https://www.ncbi.nlm.nih.gov/pubmed/30294606
http://dx.doi.org/10.12998/wjcc.v6.i11.418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163141/
https://www.ncbi.nlm.nih.gov/pubmed/30294606
http://dx.doi.org/10.12998/wjcc.v6.i11.418

Ejemplares similares